Form 4: Corbus Pharmaceuticals Director Peter Salzmann Receives Stock Grant

Director Peter Salzmann of Corbus Pharmaceuticals Holdings, Inc. was granted 2,783 restricted stock units (RSUs) on May 30, 2024, which will vest in one year.

Summary

• Peter Salzmann, a director of Corbus Pharmaceuticals Holdings, Inc., filed a Form 4 on June 3, 2024, reporting a transaction.
• On May 30, 2024, Salzmann was granted 2,783 restricted stock units (RSUs).
• These RSUs will be settled in shares of common stock with a par value of $0.0001.
• The RSUs will vest 100% on the one-year anniversary of the grant date.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral event with a slightly positive implication for corporate governance.

Positives

• The grant of RSUs to a director aligns their interests with those of the shareholders.

Future Outlook

The RSUs will vest in one year, potentially increasing Salzmann's stake in the company.

Industry Context

Grants of restricted stock units are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The RSU grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates